Overview

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study will have 3 parallel arms and approximately 30 patients will be equally randomized to one of two dose regimens of PHA-022121 or matching placebo. The screening period is up to 8 weeks and the treatment period is 12 weeks in duration. The study will assess the efficacy of PHA-022121 as prophylaxis against HAE attacks, and safety of each dose of PHA-022121 compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Pharvaris Netherlands B.V.